This report describes a 54-year-old male with chronic HCV-related cirrhosis who presented with multifocal, unresectable hepatocellular carcinoma (HCC). The clinical course was complicated by tumor rupture with resultant hemoperitoneum. At presentation the tumor burden and acute complication rendered surgery not indicated.
The authors classify the tumor stage as BCLC C, indicating advanced disease. Because of the unresectable multifocal nature of the tumor and the acute hemorrhagic complication, the patient was not considered a candidate for immediate surgical resection.
To pursue potential tumor control and downstaging, the patient was enrolled in a Phase I/IIa clinical trial combining intralesional oncolytic immunotherapy Pexa-Vec with systemic immune checkpoint blockade via Nivolumab. The trial regimen as reported in the Abstract included intralesional administration of Pexa-Vec plus intravenous Nivolumab at a dose of 240 mg every 14 days.
The Abstract notes the patient received three intralesional administrations of Pexa-Vec; however, the accessible text is truncated and does not provide the complete sequence of administrations, the total number of Pexa-Vec doses intended by the protocol, or the total duration of combined therapy.
Percutaneous tumor biopsies were performed and confirmed Edmondson–Steiner grade 2 HCC. The report indicates that clinical, laboratory, and imaging follow-up were performed throughout the therapy period, implying serial assessment of tumor status and organ function while the patient received combined immunotherapy.
The Abstract does not include additional diagnostic details such as specific imaging modalities, baseline tumor measurements, alpha-fetoprotein levels, or other staging investigations in the truncated excerpt.
The authors report that the patient achieved a period of stable disease during follow-up. After four years of stable disease on therapy and surveillance, the patient underwent pre-transplant screening for liver transplantation (LT).
Details regarding the criteria used to define stable disease, the timing and findings of serial imaging studies, tumor marker trends, or any episodes of progression or immune-related adverse events during this four‑year interval are not provided in the available Abstract text.
After four years of stable disease, the patient entered pre-transplant screening and ultimately proceeded to liver transplantation according to the Abstract summary. The central message of the case report is that combined oncolytic immunotherapy with Pexa-Vec and PD‑1 blockade (Nivolumab) may serve as a bridging or downstaging strategy that can render otherwise ineligible patients suitable candidates for liver transplantation.
The truncated source does not include details of the pre-transplant evaluation process, the transplant indication used by the multidisciplinary team, perioperative management, explant pathology results, postoperative course, immunosuppression regimen after transplant, or the patient’s long-term oncologic and graft outcomes.
This summarized Abstract provides the study aim, the basic clinical scenario, trial enrollment and the dosing schedule for Nivolumab, confirmation of tumor grade by biopsy, and the high-level outcome that the patient underwent pre-transplant evaluation after four years of stable disease. Several important clinical and methodological details are not available in the excerpt provided:
Because the publicly available source text is incomplete, readers should consult the full published case report for comprehensive data on treatment chronology, response metrics, safety signals, transplant details, and follow-up outcomes if those specifics are required for clinical decision-making or citation.
From the information provided in the Abstract, this case exemplifies a situation in which combined intralesional oncolytic virus therapy (Pexa-Vec) and systemic PD‑1 inhibition (Nivolumab) were used in a patient with advanced, ruptured HCC to achieve disease control sufficient to permit evaluation for liver transplantation after an extended period of surveillance (reported as four years of stable disease).
The authors present the case to highlight the potential of immunotherapy-based strategies as bridging or downstaging options in patients who would otherwise be ineligible for curative-intent transplant due to advanced tumor stage or complications such as rupture. However, because detailed efficacy and safety data are not available in the truncated Abstract, the role of such approaches should be interpreted cautiously and in the context of multidisciplinary evaluation and prospective evidence.
Note: The source Abstract available here is truncated and does not report full treatment details, response data, transplant perioperative course, or long-term post-transplant outcomes. Those missing specifics were not reported in the accessible source text and must be obtained from the full published article for complete clinical appraisal.